1
112 Tuberculosis Rocsanna Namdar, Michael Lauzardo, and Charles A. Peloquin Upon completion of the chapter, the reader will be able to: 1 Compare the risk for active tuberculosis (TB) disease among patients based on their age, immune status, place of birth, and time since exposure to an active case. 2 Design an appropriate therapeutic plan for an immunocompetent, immunocompromised, and pediatric patient with pulmonary TB. 3 Distinguish between the diagnostic tests used for patients potentially infected with tTB. 4 Assess the effectiveness of therapy in TB patients. 5 Describe the common and important adverse drug effects caused by TB drugs. 6 Select patients for whom therapeutic drug monitoring (TDM) may be valuable and identify the necessary laboratory monitoring parameters for patients on antituberculosis medications. 7 Design appropriate antimicrobial regimens for the treatment of latent TB infection (LTBI). LEARNING OBJECTIVES

Tuberculosis - Pharmacotherapy€¦ · Tuberculosis 112 Rocsanna Namdar, Michael Lauzardo, and Charles A. Peloquin Upon completion of the chapter, the reader will be able to: 1 Compare

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Tuberculosis - Pharmacotherapy€¦ · Tuberculosis 112 Rocsanna Namdar, Michael Lauzardo, and Charles A. Peloquin Upon completion of the chapter, the reader will be able to: 1 Compare

112TuberculosisRocsanna Namdar, Michael Lauzardo, and Charles A. Peloquin

Upon completion of the chapter, the reader will be able to:

1 Compare the risk for active tuberculosis (TB) disease among patients based on their age, immune status, place of birth, and time since exposure to an active case.

2 Design an appropriate therapeutic plan for an immunocompetent, immunocompromised, and pediatric patient with pulmonary TB.3 Distinguish between the diagnostic tests used for patients potentially infected with tTB.4 Assess the effectiveness of therapy in TB patients.5 Describe the common and important adverse drug effects caused by TB drugs.6 Select patients for whom therapeutic drug monitoring (TDM) may be valuable and identify the necessary laboratory monitoring

parameters for patients on antituberculosis medications.7 Design appropriate antimicrobial regimens for the treatment of latent TB infection (LTBI).

LEARNING OBJECTIVES